A phase III, randomized, double-blind, multicenter, active control study of Pro-NETU for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving Cisplatin based highly emetogenic chemotherapy (HEC)
Latest Information Update: 20 Sep 2023
Price :
$35 *
At a glance
- Drugs Fosnetupitant (Primary) ; Dexamethasone; Fosaprepitant; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CONSOLE
- Sponsors Taiho Pharmaceutical
- 16 Sep 2023 Results of pooled Pooled Analysis from JapicCTI163355, JapicCTI194691 and JapicCTI194611 Studies evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase, published in the Advances in Therapy
- 28 Mar 2022 According to a Taiho Pharmaceutical media release, the company has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug Arokaris I.V. Infusion 235mg for gastrointestinal symptoms associated with cancer chemotherapy.
- 18 Nov 2021 Results published in the Journal of Clinical Oncology